TY - JOUR
T1 - Evaluation of sars-cov-2 serological testing in patients with multiple myeloma and other hematologic malignancies on monoclonal antibody therapies
AU - Mahimainathan, Lenin
AU - Narasimhan, Madhusudhanan
AU - Corchado, Rolando
AU - Patel, Hetalkumari
AU - Kansagra, Ankit
AU - Devaraj, Sridevi
AU - Geethakumari, Praveen Ramakrishnan
AU - Muthukumar, Alagarraju
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/12
Y1 - 2020/12
N2 - Background: Patients with hematological malignancies (HM), including multiple myeloma (MM), frequently suffer from immune deficiency-associated infectious complications because of both the disease and the treatment. Alarming results from China and the UK confirm the vulnerability of HM patients to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-driven coronavirus disease 2019 (COVID-19). Given that the immunoassay interference from the endogenous monoclonal immunoglobulin (M paraprotein) and treatment antibodies continually challenges the MM management, it is critical to evaluate the SARS-CoV-2 serology tests for suspected interference/cross-reactivity. Methods: We compared the degree of interference in three SARS-CoV-2 serology assay platforms in HM patients with and without COVID-19 and on various therapeutic monoclonal antibody (t-mAb) treatments. Further, we confirmed the cross-reactivity in pooled samples from normal and COVID-19 + samples spiked with respective antibodies in vitro. Results: None of the 93 HM patient samples with or without t-MAbs showed cross-reactivity on any of the three serology platforms tested. Conclusions: The tested three serologic assays for SARS-CoV-2 are specific and do not have cross-reactivity with M-components or t-MAbs indicating that they can be used safely in oncology practice and in research exploring the immunologic response to COVID-19 in patients with HM.
AB - Background: Patients with hematological malignancies (HM), including multiple myeloma (MM), frequently suffer from immune deficiency-associated infectious complications because of both the disease and the treatment. Alarming results from China and the UK confirm the vulnerability of HM patients to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-driven coronavirus disease 2019 (COVID-19). Given that the immunoassay interference from the endogenous monoclonal immunoglobulin (M paraprotein) and treatment antibodies continually challenges the MM management, it is critical to evaluate the SARS-CoV-2 serology tests for suspected interference/cross-reactivity. Methods: We compared the degree of interference in three SARS-CoV-2 serology assay platforms in HM patients with and without COVID-19 and on various therapeutic monoclonal antibody (t-mAb) treatments. Further, we confirmed the cross-reactivity in pooled samples from normal and COVID-19 + samples spiked with respective antibodies in vitro. Results: None of the 93 HM patient samples with or without t-MAbs showed cross-reactivity on any of the three serology platforms tested. Conclusions: The tested three serologic assays for SARS-CoV-2 are specific and do not have cross-reactivity with M-components or t-MAbs indicating that they can be used safely in oncology practice and in research exploring the immunologic response to COVID-19 in patients with HM.
KW - COVID-19
KW - Cross-reactivity
KW - Hematological malignancy
KW - M-spike
KW - Multiple myeloma
KW - SARS-CoV-2
KW - Serology
KW - Therapeutic monoclonal antibodies
UR - http://www.scopus.com/inward/record.url?scp=85109091244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109091244&partnerID=8YFLogxK
U2 - 10.3390/diagnostics10120992
DO - 10.3390/diagnostics10120992
M3 - Article
C2 - 33255154
AN - SCOPUS:85109091244
SN - 2075-4418
VL - 10
JO - Diagnostics
JF - Diagnostics
IS - 12
M1 - 992
ER -